Amgen, headquartered in Thousand Oaks, California, is a biotechnology company employing 26,700 staff, focusing on developing human therapeutics for high unmet medical needs. Its product portfolio includes Aranesp, ENBREL, and Prolia, among others.
Nancy A Grygiel sold 1,267 shares of AMGN on 20 August at $296.99 per share, worth a total of $376K. They now own 7,209 AMGN shares, or a 15% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
